FDA approves Mylan's generic Sular

PITTSBURGH Mylan Pharmaceuticals has received final approval from the Food and Drug Administration for a generic version of Sciele Pharma’s hypertension drug Sular ER.

The generic, Nisoldipine extended-release tablets will be available in 20, 30 and 40 mg strengths.

According to Mylan, these three milligrams of Sular ER had combined sales in the U.S. of about $94 million for the 12 months that ended March 31, 2008.